Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prelude Therapeutics (PRLD) Total Non-Current Liabilities (2024 - 2025)

Historic Total Non-Current Liabilities for Prelude Therapeutics (PRLD) over the last 2 years, with Q3 2025 value amounting to $33.3 million.

  • Prelude Therapeutics' Total Non-Current Liabilities fell 1147.57% to $33.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $33.3 million, marking a year-over-year decrease of 1147.57%. This contributed to the annual value of $41.0 million for FY2024, which is N/A changed from last year.
  • Latest data reveals that Prelude Therapeutics reported Total Non-Current Liabilities of $33.3 million as of Q3 2025, which was down 1147.57% from $36.1 million recorded in Q2 2025.
  • Over the past 5 years, Prelude Therapeutics' Total Non-Current Liabilities peaked at $41.0 million during Q4 2024, and registered a low of $33.1 million during Q1 2024.